Trospium Chloride (trospium chloride)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Trospium chloride, a quaternary ammonium antimuscarinic, is a genitourinary antispasmodic.
Trospium chloride, a quaternary ammonium antimuscarinic, antagonizes acetylcholine at muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the urinary bladder. In urodynamic studies in patients with conditions characterized by involuntary detrusor contractions, trospium increased maximum cystometric capacity and volume at first detrusor contraction.
At concentrations achieved following usual therapeutic doses of the drug, trospium has little or no affinity for nicotinic receptors compared with muscarinic receptors.
Trospium chloride is incompletely absorbed from the GI tract following oral administration. The mean absolute oral bioavailability is about 9.6%. Administration of trospium chloride with a high-fat meal reduces systemic exposure to and peak plasma concentrations of the drug by about 70-80%.
The drug is hydrophilic and theoretically should not cross the blood-brain barrier like lipophilic anticholinergic drugs (e.g., oxybutynin, tolterodine); therefore, adverse CNS effects (e.g., dizziness) should be minimal. Following oral administration of radiolabeled trospium chloride, approximately 85% of the dose was excreted in feces and about 5.8% was eliminated in urine; unchanged drug accounted for about 60% of the recovered radioactivity in urine. Active tubular secretion is a major route of elimination of trospium, implying possible competition for renal secretion with other drugs that are eliminated by the same route. (See Drug Interactions.) Metabolic pathways of trospium have not been fully elucidated to date; however, the cytochrome P-450 (CYP) enzyme system is not expected to contribute substantially to elimination of the drug.
Based on in vitro studies, trospium does not appear likely to inhibit CYP isoenzymes 1A2, 3A4, 2A6, 2C9, 2C19, 2D6, or 2E1 at clinically relevant concentrations.
USES: This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, trospium improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom.
Trospium belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.
Generic name: trospium chloride
Pronunciation: (TROSE-pee-um)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Trospium Chloride
Indications
The following indications are listed for Trospium Chloride:
- Bladder Hyperactivity
- Increased Urinary Frequency
- Urinary Urge Incontinence
- Urinary Urgency
Also known as: Detrusor Overactivity, Hypertonic Bladder, Hypertonicity Of Bladder, Low Compliance Of Bladder, Overactive Detrusor, Urge Incontinence, Urge Urinary Incontinence, Urinary Frequency.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Urinary retention, gastric retention, or uncontrolled angle-closure glaucoma or risk of these conditions.
Known hypersensitivity to trospium chloride or any ingredient in the formulation.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects occurring in 5% or more of patients receiving trospium include dry mouth and constipation.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy not established in pediatric patients.
Category C. (See Users Guide.)
Distributed into milk in small amounts in rats; not known whether trospium is distributed into human milk. Use with caution in nursing women and only if potential benefit justifies the risk to the infant.
In patients 75 years of age and older, an increased incidence of adverse anticholinergic effects unrelated to drug exposure was observed; therefore, dosage may be reduced in such patients depending on patient tolerance. (See Dosage and Administration: Special Populations.)
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.